Roche, Celgene blood cancer drugs to be top draws at US meeting
This article was originally published in Scrip
Executive Summary
New data for Roche’s recently approved leukemia treatment Gazyva and Celgene’s biggest product, Revlimid, will be among the top draws at a major US medical meeting focused on blood diseases next month.